Prosecution Insights
Last updated: October 25, 2026
Application No. 18/178,778

PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER

Non-Final OA §DOUBLEPATENT
Filed
Mar 06, 2023
Priority
Nov 21, 2013 — CIP of 14/086,696 +6 more
Examiner
CANELLA, KAREN A
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Apeiron Biologics GmbH
OA Round
2 (Non-Final)
62%
Grant Probability
Moderate
2-3
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
711 granted / 1142 resolved
+2.3% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
49 currently pending
Career history
1198
Total Applications
across all art units

Statute-Specific Performance

§101
6.7%
-33.3% vs TC avg
§103
24.2%
-15.8% vs TC avg
§102
16.6%
-23.4% vs TC avg
§112
33.0%
-7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1142 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 28-36 are pending and under consideration. The rejection of claims 28-32 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is withdrawn in light of applicant’s arguments. The rejection of claims 28-36 on the ground of nonstatutory double patenting as being unpatentable over claims 1-26 of U.S. Patent No.11,492,412 is withdrawn in light of applicant’s TD. The rejection of claims 28-31 and 34-36 on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No.10,995,147 is withdrawn in light of applicant’s TD. New Grounds of Rejection The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 28, 29, 30, 31, 32, 33, and 34 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-25 of copending Application No. 19/404,977 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the application anticipate the instant claims to the extent that the instant claims do not further require administration of Il-2 in the same treatment cycle or in the same overall treatment period. Claim 1 of the application meets the limitations of instant claims 28-31 and 34-36 wherein the antibody is ch14.18/SP2/0 and the pediatric patient is administered 17.5 X 4= 70mg/m2/cycle. Claim 2 of the application meets the limitations of claims 28, 30-34 and 36 wherein the antibody is ch14.18/CHO or ch14.18/SP2/0 and the dose per cycle is 17.5 X 4= 70mg/m2/cycle. Claim 3 of the application meets the limitations of claims 29 and 35 This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Section 804 I(1)(b)(ii) of the M.P.E.P. states: If both the application under examination and the reference application have the same patent term filing date, the provisional nonstatutory double patenting rejection made in each application should be maintained until it is overcome. Provisional nonstatutory double patenting rejections are subject to the requirements of 37 CFR 1.111(b). Thus, applicant can overcome a provisional nonstatutory double patenting rejection by filing a reply that either shows that the claims subject to the rejection are patentably distinct from the claims of the reference application, or includes a compliant terminal disclaimer under 37 CFR 1.321 that obviates the rejection. If the reply is sufficient, the examiner will withdraw the nonstatutory double patenting rejection in the application in which it was submitted. In the instant case, both 19404,977 and the instant application have the same patent-term filing date of November 21, 2013. Thus, the rejection above cannot be withdrawn without filing of a terminal disclaimer or amendment to provide patentably distinct claims in either application All claims are rejected. All other rejections as set forth in the prior Office action are withdrawn. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAREN A CANELLA whose telephone number is (571)272-0828. The examiner can normally be reached M-F 10-6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. KAREN A. CANELLA Examiner Art Unit 1643 /Karen A. Canella/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Mar 06, 2023
Application Filed
Jan 23, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Jul 22, 2026
Response Filed
Oct 05, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760275
GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF
2y 1m to grant Granted Oct 13, 2026
Patent 12753393
LIQUID CRYSTAL SCAFFOLDS AND USE THEREOF FOR ORGANOID, SPHEROID, AND 3D CELLAGGREGATE MANUFACTURING
1y 3m to grant Granted Oct 06, 2026
Patent 12747250
CAMPTOTHECIN DERIVATIVES
4y 11m to grant Granted Sep 29, 2026
Patent 12747265
FOXM1-DERIVED PEPTIDE, AND VACCINE INCLUDING SAME
4y 9m to grant Granted Sep 29, 2026
Patent 12734209
CD38 Antibody Drug Conjugate
4y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
62%
Grant Probability
95%
With Interview (+32.8%)
3y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1142 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month